Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Trospium chloride in children: dynamic changes of the residual urine symptom during treatment of urination disorders

Trospium chloride in children: dynamic changes of the residual urine symptom during treatment of urination disorders

Vadim. V. Danilov , Olesya B. Golovina , Valeriy V. Danilov

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Background. A significant place among pediatric urination disorders is occupied by overactive bladder (OAB). Treatment involving the use of M-anticholinergics is aimed to suppress detrusor overactivity. The side effects of treatment include urination problems, incomplete bladder emptying (residual urine), and acute urinary retention. Methods. We monitored 20 children aged 5–15 years, among them 12 boys and 8 girls. The average age (М±δ) was 8.47 ± 3.46 years. The 2-day uroflow monitoring revealed residual urine (RU) in 9 patients (1–15 times per monitoring period). The urination volume and rate, as well as RU, were assessed by uroflow monitoring conducted at home using the SIGMA F uroflowmeter (RZN registration certificate No. 2020/11522 of 5.08.2020). One of the components of combination therapy was trospium chloride (Spasmex) in a dose of 10–15 mg per day, depending on the age and disorder. Statistical data processing was performed using the STATISTICA 10 (StatSoft, Inc., USA) and Excel (Microsoft Office 2016) software packages. The differences were considered significant at p<0.05. The descriptive statistics were presented as М±δ (where М was median, δ was standard deviation).
Results. The average effective volume (AEV) of urination in the group was reduced by 10–86.5% relative to the age norm. Furthermore, incomplete bladder emptying was reported in 9 patients. After treatment, the minimum urine output volume and the maximum urine flow rate increased significantly, while the urination rate decreased. There were no significant changes in the urine output volume (average and maximum), however, an upward trend of the urine output volume was observed. No increase in the number of RU cases following prescription of trospium chloride was reported. In fact, the decrease in their number was recorded. Conclusion. Pediatric micturition cycle abnormalities also include the RU symptom. The M-anticholinergic drug, trospium chloride (Spasmex), in a daily dose of 10-15 mg represents a safe and effective medication option. Therapy lasting up to 2 months results in the significant increase in minimum bladder volume and maximum urine flow rate, the decrease in pollakiuria severity, but never changes the rate and amount of residual urine.
Keywords: urination disorders, children, uroflowmetry, uroflow monitoring, trospium chloride, residual urine.

About the Author

Vadim. V. Danilov 1 , Olesya B. Golovina 2 , Valeriy V. Danilov 3

1 Pacific State Medical University, Vladivostok, Russia

2 Pacific State Medical University, Vladivostok, Russia; “Alenka” Medical Center, Vladivostok, Russia

3 Far Eastern Federal University, Vladivostok, Russia

References

1. Бурлуцкая А.В., Мартыненко В.В. Гиперактивный мочевой пузырь у детей: клинические и параклинические особенности. Глобальные проблемы современности. 2021;2(1):48-51.  Burlutskaya A.V., Martynenko V.V. Hyperactive bladder in children: clinical and paraclinical features. Globalnye problemy sovremennosti. 2021;2(1):48-51 (in Russian).
2. Воробьева Ю.Д., Сытьков В.В., Зокиров Н.З. и др. Гиперактивный мочевой пузырь у детей: новое в диагностике и лечении. Российский педиатрический журнал. 2020;23(5):330-4.  Vorobyova Yu.D., Sytkovo V.V., Zokirov N.Z. et al. Hyperactive bladder in children: new in diagnosis and treatment. Russian Pediatric Journal. 2020;23(5):330-4 (in Russian).
3. Шапошникова Н.Ф., Давыдова А.Н. Нейрогенная дисфункция мочевого пузыря у детей и методы ее ранней диагностики и лечения. Лекарственный вестник. 2017;11(4):19-23. Shaposhnikova N.F., Davydova A.N. Neurogenic bladder dysfunction in children and methods of its early diagnosis and treatment. Medicinal bulletin. 2017;11(4):19-23 (in Russian).
4. Fuentes M, Magalhгes J, Barroso U. Diagnosis and management of bladder dysfunction in neurologically normal children. Front Pediatr. 2019;7:298. DOI: 10.3389/fped.2019.00298
5. Kopiczko N, Dzik-Sawczuk A, Szwarc K et al. Analysis of Indications for Voiding Cystography in Children. J Clin Med. 2021;10(24):5809. DOI: 10.3390/jcm10245809
6. Данилов В.В. Феномен детрузорной гиперактивности как проявление патологического вегетативного рефлекса. Фарматека. 2021;28(3):113-9. DOI: 10.18565/pharmateca.2021.3.113-119 Danilov V.V. The phenomenon of detrusor hyperactivity as a manifestation of a pathological vegetative reflex. Pharmateca. 2021;28(3):113-9. DOI: 10.18565/pharmateca.2021.3.113-119 (in Russian).
7. Данилов В.В., Вольных И.Ю., Данилов В.В., Данилов В.В. Коррекция расстройств мочеиспускания в раннем послеоперационном периоде после троакарного синтетического слинга. Фарматека. 2023;30(9-10):208-12. DOI: 10.18565/pharmateca.2023.9-10.208-212 Danilov V.V., Volnykh I.Yu., Danilov V.V., Danilov V.V. Correction of urination disorders in the early postoperative period after trocar synthetic sling. Pharmateca. 2023;30(9-10):208-12. DOI: 10.18565/pharmateca.2023.9-10.208-212 (in Russian).
8. Данилов В.В., Вольных И.Ю., Данилов В.В., Данилов В.В. Изменение уровня детрузорной гиперактивности при длительном назначении М-холинолитика. Фарматека. 2023;30(4-5):79-83. DOI: 10.18565/pharmateca.2023.4-5.79-83 Danilov V.V., Volnykh I.Yu., Danilov V.V., Danilov V.V. Changes in the level of detrusor hyperactivity during prolonged administration of M-cholinolytic. Pharmateca. 2023;30(4-5):79-83. DOI: 10.18565/pharmateca.2023.4-5.79-83 (in Russian).
9. Данилов В.В., Вольных И.Ю. Обоснование назначения троспия хлорида в первой линии терапии при гиперактивном мочевом пузыре. Фарматека. 2023;30(1-2):226-31. DOI: 10.18565/pharmateca.2023.1-2.226-230 Danilov V.V., Volnykh I.Yu. Justification of the appointment of trospium chloride in the first line of therapy for overactive bladder. Pharmateca. 2023;30(1-2):226-31. DOI: 10.18565/pharmateca.2023.1-2.226-230 (in Russian).
10. Franco I, Hoebeke P, Baka-Ostrowska M et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatric Urology. 2020;16:180.e1-180e8.
11. Snijder R, Bosman B, Stroosma O, Agema M. Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial. Eur J Pediatr. 2020;179(10):1523-8. DOI: 10.1007/s00431-020-03635-2
12. Yamato Sano, Satoshi Shoji, Mohamed Shahin et al. Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity. Eur J Drug Metabol Pharmacokinetics. 2023;48:257-69.
13. Vidal – справочник лекарственных средств.  Vidal – directory of medicines. (in Russian).
14. Данилов В.В., Данилов В.В. Нейроурология. Том 1. Владивосток, 2019. Danilov V.V., Danilov V.V. Neurology. Volume 1. Vladivostok, 2019 (in Russian).
15. Petzinger E, Gavrilova O, Geyer J, Schwantes U. The role of the MDR1 transporter in body distribution and brain penetration of the trospium chloride and oxybutynin. Eur Urol Suppl. 2008;7(3):675. DOI: 10.1016/s1569-9056(08)60673-9

For citation:Danilov V.V., Golovina O.B., Danilov V.V. Trospium chloride in children: dynamic changes of the residual urine symptom during treatment of urination disorders. Clinical review for general practice. 2024; 5 (3): 99–104. DOI: 10.47407/kr2023.5.3.00367


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru